Filing Flows › Fulgent Genetics (FLGT) › Q1 2025
Fulgent Genetics (FLGT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 2, 2025
Fulgent Genetics (FLGT) reported revenue of $73.5M for the first quarter 2025 (Q1 2025), +14% from a year earlier and -4% from the quarter before. Operating margin was -26.9%, net loss $11.9M (16.2% of revenue).
Fulgent Genetics, Q1 2025: revenue $73.5M (+14% year over year), operating margin -26.9%, net loss $11.9M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $73.5M | -4% | +14% |
| Operating profit | −$19.8M | — | — |
| Net earnings | −$11.9M | — | — |
| Operating cash flow | −$4.4M | — | — |
What changed
Revenue was $73.5M in Q1 2025, up 14% year over year and down 4% from the previous quarter.
Gross margin was 38.6%, up 4.3 points from a year earlier. Operating costs exceeded revenue by $19.8M, an operating margin of -26.9%. Operating expenses grew 10% against revenue growth of 14%. The fastest-growing cost line was General & admin (+18%). The quarter ended with a net loss of $11.9M, wider than the previous quarter's $6.2M loss. Minority interests bore $369K of it: to shareholders the quarter was a loss of $11.5M. Non-operating items added $8.1M, -69% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.4M. Non-cash charges added back $5.9M of depreciation and amortization and $10.6M of share-based compensation. Working capital and other items used $9.0M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$9.1M.
Questions
What was Fulgent Genetics' revenue in the first quarter 2025?
Fulgent Genetics (FLGT) reported revenue of $73.5M for the first quarter 2025 (Q1 2025), +14% from a year earlier and -4% from the quarter before.
Was Fulgent Genetics profitable in the first quarter 2025?
Operating loss was $19.8M (-26.9% of revenue) and net loss $11.9M.
Source: Fulgent Genetics 10-Q on SEC EDGAR.